Summary of key recommendations: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) | ||
*Age 75 y and no safety concerns: High-intensity statin. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])<nowiki>"</nowiki> | *Age 75 y and no safety concerns: High-intensity statin. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])<nowiki>"</nowiki> | ||
*Age >75 y or safety concerns: Moderate-intensity statin. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | *Age >75 y or safety concerns: Moderate-intensity statin. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) ''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
*Rule out secondary causes of hyperlipidemia ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])<nowiki>"</nowiki> | *Rule out secondary causes of hyperlipidemia ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])<nowiki>"</nowiki> | ||
*Age !21 y: High-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | *Age !21 y: High-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) ''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL | ||
Revision as of 17:59, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
| Class I |
"1.Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin)
|
"2.Primary prevention – Primary LDL-C ‡190 mg/dL(Level of Evidence: B)"
|
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL
|
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
|
| Class III (Harm) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class III (No Benefit) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIa |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIb |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |